Literature DB >> 6340275

Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation.

M S Kennedy, H J Deeg, M Siegel, J J Crowley, R Storb, E D Thomas.   

Abstract

The role of cyclosporine alone or in combination with amphotericin B in the development of renal toxicity was evaluated in 47 marrow transplant recipients. Cyclosporine alone was given to 21 patients and 10 received cyclosporine plus amphotericin B. These were compared with 16 patients who received methotrexate and amphotericin B. Serum creatinine doubled within 14-30 days in 8 of 21 patients who received only cyclosporine. Of 16 patients given amphotericin B in conjunction with methotrexate, only 3 doubled their serum creatinine within 5 days of starting amphotericin B. In contrast, of 10 patients who received amphotericin B in combination with cyclosporine, 5 doubled and 3 tripled their serum creatinine within 5 days. This increase in creatinine was significantly greater than that seen in patients receiving cyclosporine alone or methotrexate and amphotericin B combined. These results suggest that administration of cyclosporine and amphotericin B simultaneously should be undertaken with caution to avoid severe renal toxicity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6340275     DOI: 10.1097/00007890-198303000-00005

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  21 in total

1.  Systemic antifungal agents.

Authors:  L O Gentry
Journal:  Tex Heart Inst J       Date:  1990

2.  Cryptococcal cerebrospinal fluid shunt infection treated with fluconazole.

Authors:  D Eymard; F Lebel
Journal:  Can J Infect Dis       Date:  1993-07

Review 3.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 4.  Complications of cyclosporin therapy.

Authors:  B D Kahan; S M Flechner; M I Lorber; C Jensen; D Golden; C T Van Buren
Journal:  World J Surg       Date:  1986-06       Impact factor: 3.352

5.  Prevalence and nature of potential drug-drug interactions among kidney transplant patients in a German intensive care unit.

Authors:  Julia Amkreutz; Alexander Koch; Lukas Buendgens; Anja Muehlfeld; Christian Trautwein; Albrecht Eisert
Journal:  Int J Clin Pharm       Date:  2017-08-19

6.  Ceftazidime does not enhance cyclosporin-A nephrotoxicity in febrile bone marrow transplantation patients.

Authors:  C Verhagen; B E de Pauw; T de Witte; R S Holdrinet; J T Janssen; K J Williams
Journal:  Blut       Date:  1986-10

7.  Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma.

Authors:  J Berenguer; N M Ali; M C Allende; J Lee; K Garrett; S Battaglia; S C Piscitelli; M G Rinaldi; P A Pizzo; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

8.  Blood and tissue distribution of cyclosporin A after a single oral dose in the rat.

Authors:  K Nooter; B Meershoek; W Spaans; P Sonneveld; R Oostrum; J Deurloo
Journal:  Experientia       Date:  1984-06-15

Review 9.  Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.

Authors:  C A Lyman; T J Walsh
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

Review 10.  Clinical pharmacokinetics of cyclosporin.

Authors:  R J Ptachcinski; R Venkataramanan; G J Burckart
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.